A Study Evaluating Amplex Compared To Autograft Bone In Foot and Ankle Fusion Surgery

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01224119
Recruitment Status : Unknown
Verified March 2012 by BioSurface Engineering Technologies, Inc.
Recruitment status was:  Active, not recruiting
First Posted : October 19, 2010
Last Update Posted : March 9, 2012
Information provided by (Responsible Party):
BioSurface Engineering Technologies, Inc

Brief Summary:

The current research study evaluates an investigational medical device called Amplex B2A(TM) Peptide Enhanced Ceramic Granules ("Amplex") for use in foot and ankle fusion. Amplex is a synthetic bone graft material. The most frequently used graft material is bone collected from the patient (autograft). Autograft involves a secondary incision with the risks of infection and lasting pain.

The purpose of this study is to determine if Amplex is a safe and effective alternative to autograft.

Condition or disease Intervention/treatment Phase
Arthritis Device: Amplex Procedure: Autograft bone Phase 1 Phase 2

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 24 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Multi-Center, Randomized, Pilot Study Evaluating Amplex Compared To Autograft Bone In Foot and Ankle Fusion Surgery
Study Start Date : January 2011
Estimated Primary Completion Date : April 2012
Estimated Study Completion Date : April 2012

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Experimental: Amplex (synthetic bone graft) Device: Amplex
225 micrograms of B2A per cc of ceramic granules
Active Comparator: Autograft bone Procedure: Autograft bone
Bone is collected through a separate incision at the iliac crest or tibia.

Primary Outcome Measures :
  1. Radiographic fusion [ Time Frame: 6 months ]
    An independent radiologist will assess radiographic fusion based upon CT imaging.

  2. Ankle Osteoarthritis Questionnaire [ Time Frame: 6 months ]
    This is a questionnaire completed by the subject. It consists of a number of questions concerning the amount of pain in the foot and its effect on functional activities.

Secondary Outcome Measures :
  1. Ankle Osteoarthritis Questionnaire [ Time Frame: 12 months ]
    The is a questionnaire completed by the subject. Its asks a series of questions about pain and function of the treated foot or ankle.

  2. Radiographic fusion [ Time Frame: 9-12 months ]
    Radiographic fusion will be assess by a blinded indpenendent radiologists, using CT and X-ray images. The investigator will also assess fusion based on the images and also the overall condition of the subject.

  3. Various blood tests [ Time Frame: PreOp through 6 months ]
    Small amounts of blood will be collected at study visits to identify possible changes in blood chemistry, liver function and antibody formation.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Indicated for foot and ankle surgery described as either a single, double or triple arthrodesis of the ankle, subtalar, calcaneocuboid or talonavicular joints.
  • Have the ability to understand the requirements of the study, to provide written informed consent, and to comply with the study protocol
  • Have the ability to understand and provide written authorization for the use and disclosure of personal health information (PHI)
  • Be a skeletally mature male or a non-pregnant, non-lactating female at least 18 years of age but not older than age 75
  • If a woman is of childbearing potential (not amenorrheic for the previous 24 months or not surgically sterile), then she must:

    • Have a confirmed negative urine pregnancy test result prior to surgery and the administration of the study product
    • Agree to use a medically approved method of contraception for the duration of the initial follow-up period of the study
  • Agree to participate in postoperative clinical and radiographic evaluations and comply with the required study regimen
  • Have not been sufficiently responsive to an adequate trial of non-operative treatment (e.g. modified activity, analgesics, anti-inflammatories, bracing, orthotics, physiotherapy, vitamin supplements, or injections etc. prior to study enrollment).

Exclusion Criteria:

  • Has a large bone deficit requiring a structural graft
  • Charcot joints from neuropathic destruction.
  • Previous fusion or osteotomy of the proposed site
  • Requires osteotomy or fusion of the midfoot joints
  • Morbidly obese (BMI >45 kg/m2)
  • Women planning to become pregnant during the first year (12 months) following the procedure
  • Female subjects of childbearing potential unwilling to use medically acceptable contraceptive methods (e.g., surgical sterilization, hormonal contraceptives, barrier methods, or intrauterine devices) so as to prevent pregnancy for 12 months following the study procedure
  • Have at the time of surgery a systemic infection or local infection at the site of surgery
  • Have an active history of systemic malignancy.
  • Currently has untreated malignant neoplasm(s), or is currently undergoing radio- or chemotherapy or has been diagnosed with hypercalcemia.
  • Have a medical condition, serious intercurrent illness, or extenuating circumstance that, in the opinion of the Investigator, would preclude participation in the study or potentially decrease survival or interfere with ambulation or rehabilitation (e.g., histories of transient ischemic attack, stroke or liver disease)
  • Has a known complication of diabetes (e.g. retinopathy, renal failure, neuropathic complication in lower limb).
  • Uncontrolled diabetes. If the patient has been diagnosed with diabetes, they must have an Hgb A1C level less than 7 to participate.
  • Have a known hypersensitivity to any of the components of the product [e.g., Hydroxyapatite (HA): Tricalcium Phosphate (TCP) ceramic granule] or a known titanium allergy
  • Receiving active treatment with a drug known to interfere with bone metabolism (e.g. long-term steroid therapy, methotrexate).
  • Have a history of any severe allergy or anaphylaxis, or a history of hypersensitivity to protein pharmaceuticals (e.g., monoclonal antibodies or gamma globulins, recombinant BMPs)
  • Being treated with a bone growth stimulator
  • Have a medical condition requiring radiation, chemotherapy or immunosuppression.
  • Have obvious and/or documented alcohol or illicit drug addictions
  • Are prisoners
  • Have participated in clinical studies evaluating investigational devices, pharmaceuticals or biologics within 3 months of enrollment
  • Have previously been treated with, or exposed to, therapeutic levels of Bone Morphogenetic Proteins (BMPs), i.e., synthetic or recombinant
  • Have a documented medical history of or radiographic evidence of a metabolic bone disease (e.g., avascular necrosis, osteoporosis or osteopenia) or other condition that would negatively impact the bone healing process (e.g. history of Paget's disease, osteomalacia, or other osteodystrophy) or preclude the subject from receiving screw fixation.
  • Require chronic SQ or IV heparin therapies

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01224119

Canada, Nova Scotia
Dr. Mark Glazebrook
Halifax, Nova Scotia, Canada
Sponsors and Collaborators
BioSurface Engineering Technologies, Inc
Study Director: David M Hooper, PhD BioSurface Engineering Technologies, Inc
Principal Investigator: Mark Glazebrook, MD Queen Elizabeth II Health Sciences Center Halifax Infirmary

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: BioSurface Engineering Technologies, Inc Identifier: NCT01224119     History of Changes
Other Study ID Numbers: AMX-200
First Posted: October 19, 2010    Key Record Dates
Last Update Posted: March 9, 2012
Last Verified: March 2012

Keywords provided by BioSurface Engineering Technologies, Inc:
foot ankle arthritis bone graft

Additional relevant MeSH terms:
Joint Diseases
Musculoskeletal Diseases